Mimedx (MDXG) Research & Development (2011 - 2026)
Mimedx recorded quarterly Research & Development of $4.1 million in Q1 2026, down 13.04% quarter-over-quarter from $4.8 million in Q4 2025, and up 24.4% year-over-year from $3.3 million in Q1 2025.
Mimedx's Research & Development history runs 16 years deep, the most recent figure standing at $4.1 million for Q1 2026.
- In Q1 2026, Research & Development rose 24.4% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $15.9 million (up 23.99% YoY), while the FY2025 annual figure was $15.1 million, up 22.33% from the prior year.
- Research & Development came in at $4.1 million for Q1 2026 at Mimedx, down from $4.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $6.0 million in Q1 2022 to a low of -$4.7 million in Q4 2022.
- A 5-year average of $3.3 million and a median of $3.5 million in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development sank 66.6% in 2022 and surged 151.46% in 2023, its largest moves.
- Mimedx's Research & Development stood at -$4.7 million in 2022, then soared by 151.46% to $2.4 million in 2023, then jumped by 46.77% to $3.6 million in 2024, then soared by 33.32% to $4.8 million in 2025, then fell by 13.04% to $4.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $4.1 million, $4.8 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 4.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.14 Mn |
| Dec 31, 2025 | 4.76 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 3.30 Mn |
| Mar 31, 2025 | 3.33 Mn |
| Dec 31, 2024 | 3.57 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 3.01 Mn |
| Mar 31, 2024 | 2.84 Mn |
| Dec 31, 2023 | 2.43 Mn |
| Sep 30, 2023 | 3.08 Mn |
| Jun 30, 2023 | 3.67 Mn |
| Mar 31, 2023 | 3.48 Mn |
| Dec 31, 2022 | -4.73 Mn |
| Sep 30, 2022 | 5.95 Mn |
| Jun 30, 2022 | 5.51 Mn |
| Mar 31, 2022 | 5.96 Mn |
| Dec 31, 2021 | -2.84 Mn |
| Sep 30, 2021 | 4.37 Mn |
| Jun 30, 2021 | 4.06 Mn |
| Mar 31, 2021 | 4.34 Mn |
| Dec 31, 2020 | 3.43 Mn |
| Sep 30, 2020 | 3.37 Mn |
| Jun 30, 2020 | 2.26 Mn |
| Mar 31, 2020 | 2.65 Mn |
| Dec 31, 2019 | 2.72 Mn |
| Sep 30, 2019 | 2.69 Mn |
| Jun 30, 2019 | 2.83 Mn |
| Mar 31, 2019 | 2.90 Mn |
| Dec 31, 2018 | 4.54 Mn |
| Sep 30, 2018 | 3.96 Mn |
| Jun 30, 2018 | 3.72 Mn |
| Mar 31, 2018 | 3.55 Mn |
| Dec 31, 2017 | 3.47 Mn |
| Sep 30, 2017 | 5.48 Mn |
| Jun 30, 2017 | 4.75 Mn |
| Mar 31, 2017 | 4.20 Mn |
| Dec 31, 2016 | 5.76 Mn |
| Sep 30, 2016 | 2.92 Mn |
| Jun 30, 2016 | 3.17 Mn |
| Mar 31, 2016 | 2.50 Mn |
| Dec 31, 2015 | 2.34 Mn |
| Sep 30, 2015 | 2.19 Mn |
| Jun 30, 2015 | 2.05 Mn |
| Mar 31, 2015 | 1.83 Mn |
| Dec 31, 2014 | 1.85 Mn |
| Sep 30, 2014 | 2.01 Mn |
| Jun 30, 2014 | 1.80 Mn |
| Mar 31, 2014 | 1.39 Mn |
| Dec 31, 2013 | 1.38 Mn |
| Sep 30, 2013 | 1.29 Mn |
| Jun 30, 2013 | 924,468.00 |
| Mar 31, 2013 | 1.25 Mn |
| Dec 31, 2012 | 1.14 Mn |
| Sep 30, 2012 | 838,690.00 |
| Jun 30, 2012 | 503,086.00 |
| Mar 31, 2012 | 407,072.00 |
| Dec 31, 2011 | 660,592.00 |
| Sep 30, 2011 | 561,545.00 |
| Jun 30, 2011 | 791,952.00 |
| Mar 31, 2011 | 962,224.00 |